热门资讯> 正文

Neoleukin Therapeutics GAAP每股收益为-1.00美元，击败0.03美元

2024-05-10 19:46

Neoleukin Therapeutics press release (NASDAQ:NGNE): Q1 GAAP EPS of -$1.00 beats by $0.03.
Cash, cash equivalents and investments as of March 31, 2024 were $169.5 million. The Company expects current cash, cash equivalents and marketable securities to fund operations into the second half of 2026.

More on Neoleukin Therapeutics

Neurogene Stock: Gene Therapy Specialist May Break Chain Of Failed Mergers
Historical earnings data for Neoleukin Therapeutics
Financial information for Neoleukin Therapeutics

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。